Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma

European Urology

Volumn 64, Issue 1, 2013, Pages 62-70

  Busch, Jonas ^a   Seidel, Christoph ^b   Erber, Barbara ^a   Issever, Ahi Sema ^a   Hinz, Stefan ^a   Kempkensteffen, Carsten ^a   Magheli, Ahmed ^a   Miller, Kurt ^a   Grünwald, Viktor ^b   Weikert, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metastasis; mTORi; Renal cell carcinoma; Sequence therapy; Sunitinib; Targeted therapy; VEGF

Indexed keywords

BEVACIZUMAB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CATARACT; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; KIDNEY METASTASIS; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; STOMATITIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ACADEMIC MEDICAL CENTERS; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE;

EID: 84878882304     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.09.004     Document Type: Article

References (29)

1. E.J. Mills, B. Rachlis, and C. O'Regan Metastatic renal cell cancer treatments: an indirect comparison meta-analysis BMC Cancer 9 2009 34
2. J.S. Thompson Coon, Z. Liu, and H. Hoyle Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness Br J Cancer 101 2009 238 243
3. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
4. B. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
5. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
6. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
7. C. Eichelberg, R. Heuer, and F.K. Chun Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 2008 1373 1378
8. A.Z. Dudek, J. Zolnierek, and A. Dham Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
9. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34 discussion 34
10. J. Busch, C. Seidel, and C. Kempkensteffen Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors Eur Urol 60 2011 1163 1170
11. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
12. Phase II Study NCT00715182. http://clinicaltrials.gov/show/NCT00715182.
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181 The CTCAE 3.0 document can be found under http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf.
15. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
16. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
17. C. Seidel, J. Busch, and S. Weikert Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma Eur J Cancer 48 2012 1023 1030
18. J. Busch, C. Seidel, and S. Weikert Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma BMC Cancer 11 2011 295
19. D.Y. Heng, M.J. Mackenzie, and U.N. Vaishampayan Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 2012 1549 1555
20. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
21. E. Calvo, B. Escudier, and R.J. Motzer Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Eur J Cancer 48 2012 333 339
22. V. Grünwald, C. Seidel, and M. Fenner Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies Br J Cancer 105 2011 1635 1639
23. V. Grünwald, S. Weikert, and C. Seidel Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC Onkologie 34 2011 310 314
24. C. Porta, G. Procopio, and G. Carteni Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
25. J.A. Garcia, T.E. Hutson, and P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
26. C. Porta, C. Paglino, and I. Imarisio Sorafenib rechallenge in metastatic renal cell carcinoma BJU Int 110 6 Pt B 2012 E235
27. E. Herrmann, N. Marschner, and M.O. Grimm Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma World J Urol 29 2011 361 366
28. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
29. Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev. In press. http://dx.doi.org/10.1016/j.ctrv.2011.12.009.